Great Point Partners’s Immunic IMUX Stock Holding History

Great Point Partners’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-63,218	Closed	-$885K	–	47
2022 Q4	$885K	Buy	+63,218	New	+$1.72M	0.17%	41

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Great Point Partners's IMUX Position: Q1 2023 in Review

Great Point Partners sold out of Immunic (IMUX) in Q1 2023, closing a stake of 63,218 shares — an estimated $885K sold.

Great Point Partners first reported a position in IMUX in Q4 2022 and held it in 1 quarter. The position peaked at $885K in Q4 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2023.

Great Point Partners reported no remaining Immunic position as of Q1 2023 after selling out during the quarter.
Great Point Partners sold 63,218 Immunic shares in Q1 2023, an estimated $885K.
Great Point Partners first reported a position in Immunic in Q4 2022 and held it in 1 quarter.
Great Point Partners's Immunic position peaked at $885K in Q4 2022.
59 funds tracked by Wall St. Rank held Immunic as of Q1 2023.

Based on Great Point Partners's 13F filing for Q1 2023, filed 15 May 2023.